Guardant Health (GH) Bank of America Global Healthcare Conference 2026 summary

Financial performance and guidance

• Achieved strong Q1 results, leading to a raised full-year guidance driven by oncology and Shield volumes.

• Oncology growth is propelled by Guardant360 and the Smart Platform, with new Smart Apps expected to be catalysts throughout the year.

• Shield's momentum is supported by increased sales rep productivity, Quest collaboration, and DTC campaigns, with volume growth expected to accelerate in the second half.

• Anticipated ACS guideline changes could provide further upside, especially by expanding access to patients under 65, with revenue impact expected more in 2027.

• Screening ASPs may temporarily decline as commercial volume grows, but are expected to recover within 12 months as commercial payers come on board.

Operational strategy and market positioning

• Therapy selection and monitoring are key growth areas, with significant market expansion potential as more patients undergo repeat genomic profiling.

• The Smart Platform, launched in 2024, is driving accelerated growth and share gains, leveraging large-scale data and AI to enhance product capabilities.

• AI integration has transformed operations, automating processes across divisions and boosting R&D productivity.

• The company is investing heavily in commercial build-out for screening, aiming for scale and expecting breakeven by end of 2027.

• Compliance and regulatory processes are robust, with ongoing civil investigations viewed as routine and non-material.

Industry trends and future outlook

• Diagnostics are increasingly recognized as central to clinical decision-making, with a paradigm shift underway in oncology toward data-driven care.

• The company is well-positioned above regulatory uncertainties, with national coverage for key products and minimal exposure to recent CLFS debates.

• Ongoing innovation and data accumulation are expected to further enhance diagnostic utility and value proposition.

• Strong momentum across all business lines supports confidence in sustained growth and the next phase of expansion.